Variables | OS | PFS | TTS | ||||||
---|---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | ||||
p value | p value | HR (95% CI) | p value | p value | HR (95% CI) | p value | p value | HR (95% CI) | |
Cinical metastatic status (OPD, palliative intent) | 0.006 | 0.002 | 2.03 (1.30–3.17) | 0.002 | 0.334 | 0.053 | 0.938 | 1.0 (0.56–1.81) | |
Initial stage (I–IV) | 0.567 | – | – | 0.402 | 0.561 | ||||
Metastatic development (synchronous vs. metachronous) | 0.802 | – | – | 0.895 | 0.653 | ||||
Previous lines of systemic treatment (1 vs. > 1) | 0.166 | 0.109 | – | 0.048 | 0.033 | 1.7 (1.05–2.77) | 0.093 | 0.152 | 1.57 (0.84–2.92) |
Metastatic burden (1, 2–5, 6–10, > 10) | 0.461 | – | – | 0.062 | 0.759 | 0.051 | 0.686 | 1.10 (0.741.64) | |
Affected organs (1 vs. > 1) | 0.03 | 0.633 | – | 0.004 | 0.023 | 2.04 (1.10–3.79) | 0.026 | 0.031 | 2.53 (1.09–5.89) |
Location of metastases (cranial vs. extracranial) | 0.201 | 0.827 | – | 0.155 | 0.757 | 0.48 | |||
Histology subtype (SqCC, ADC, LCNEC, adenosquamous, unknown) | 0.952 | – | – | 0.554 | 0.447 | ||||
Gene mutation (yes vs. no) | 0.834 | – | – | 0.992 | 0.696 | ||||
Status of primary tumor (controlled vs. progressive) | 0.973 | – | – | 0.701 | 0.824 | ||||
Targeted therapy (IT, TT, AAT) | 0.855 | – | – | 0.424 | 0.64 | ||||
SRT location (cranial, extracranial, both) | 0.25 | – | – | 0.149 | 0.571 | 0.767 | |||
Number of SRT treated metastases (1–5) | 0.642 | – | – | 0.993 | 0.509 | ||||
Start targeted therapy (before, during, after SRT) | 0.239 | – | – | 0.436 | 0.299 | ||||
Targeted therapy paused during SRT (yes vs no) | 0.645 | – | – | 0.734 | 0.104 | 0.393 | 1.32 (0.75–2.34) |